7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/22/2013

Company Name Symbol %Change
ALLIANCE FIB AFOP
9.31%
SONIC FOUNDR SOFO
7.77%
VELTI PLC OR VELT
7.58%
TRI TECH HOL TRIT
6.62%
A M R CP AAMRQ
4.52%

Bayer AG - ADR (BAYRY)

by Zacks Equity Research

November 05, 2012 | Comments : 1 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Bayer AG's (BAYRY) earnings per share during the third quarter of 2012 came in at EUR1.68 (approx $1.50) compared to EUR1.12 (approx. $1.58) in the year-ago period. The company recorded an 11.5% (5.5% on an adjusted basis) growth in revenues to 9,665 million. Growth was witnessed across all major divisions at Bayer.

Bayer continues to expect 2012 earnings to increase by 10% year over year. We are impressed by Bayer's efforts to develop its pipeline. We are positive on Bayer's decision to buy nutritional supplement company Schiff Nutrition International.

Moreover, the decision of Bayer's HealthCare unit to buy Teva's animal health business in the U.S. is also a positive move. In view of these positives, we retain our Outperform recommendation on the stock.

Read the full reports :

Email Print Share Rate Pos Rate Neg

Read/Post Comments (1) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.